Analystreport

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $21.00 price target on the stock.

Zynerba Pharmaceuticals, Inc.  (ZYNE) 
Last zynerba pharmaceuticals, inc. earnings: 3/10 06:50 am Check Earnings Report
US:NASDAQ Investor Relations: ir.zynerba.com